You just read:

ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread® for Treating Hepatitis B

News provided by

ContraVir Pharmaceuticals, Inc.

Jun 01, 2016, 06:00 ET